From Legendary Biopharm to Bay Island Cells: Why Innovators Must Abandon Their Own Success

The Event

Fan Xiaohu, founder of Legendary Biopharm, launched Ciltacabtagene autoleucel—the world's first CAR-T cell therapy with annual sales approaching $2 billion. Less than a month after FDA approval in March 2022, Fan left to found Bay Island Cells. The parent company Gensing subsequently sued for "trade secret misappropriation," leading to four years of litigation. In late 2025, the Supreme Court ruled decisively in Fan's favor, followed by completion of a 140 million RMB Series A round.

Why Does This Seem Counterintuitive?

Most people's logic: if you've created the world's most successful CAR-T therapy, why leave?

But from organizational dynamics, the decision was inevitable—not for money, but because of power structures.

Layer One: Success Itself Breeds Rigidity

By 2022, Legendary Biopharm was a multi-billion-dollar listed company. Ciltacabtagene's success became an "anchor point"—defining the company's identity, investor expectations, and management decision logic.

Charles Handy observed in *The Second Curve*: the more successful an organization becomes, the more it tends to protect existing business models rather than invest in alternative innovation. This isn't conspiracy; it's financial rationality—who would allocate hundreds of millions to incubate a potentially failing next-gen therapy when a single product generates $160 million monthly revenue?

Layer Two: The Parent-Subsidiary Governance Trap

Legendary Biopharm itself was a subsidiary of Gensing. This structure contains a fatal flaw: successful subsidiary innovators cannot make independent decisions.

Fan's vision for next-generation therapies (multi-target, long-acting, low-cost variants) would potentially cannibalize Ciltacabtagene's pricing power. The parent company's finance department would invoke the logic: "don't cannibalize existing products." This isn't deliberate obstruction—it's the default rule of capital allocation—protect the cash cow, marginalize new ideas.

Layer Three: The "Quick Money Trap" for Technical Leaders

Between 2022-2024, the CAR-T market shifted from "extremely rare" to "competitive." Multiple pharma giants launched their own CAR-T offerings. Ciltacabtagene's moat was eroding with time.

Fan faced two paths:

1. Stay at Legendary Biopharm: Enjoy existing product cash flows, participate in stock appreciation, gradually become an R&D bureaucrat. In ten years, who is he? A "former innovator."

2. Leave and rebuild: Risk failure, endure legal exhaustion, but gain the chance to define next-generation therapy's commercial logic, cost structure, and market positioning.

He chose the second.

Why This Timing?

Superficially, "less than a month" seems rash. Actually, it was optimal timing—the window was closing.

• Ciltacabtagene just received approval; markets were still evaluating; competitors hadn't emerged. The founder's influence was highest, fundraising easiest, team most willing to follow.
• If he waited 2-3 years for competition to intensify and market saturation, the cost to poach talent from Legendary and build independent supply chains would increase 5-10 fold.
• Most critically: second-generation CAR-T technology roadmaps must launch before first-generation is locked in. Otherwise markets become dominated by first-gen, and later entrants become trapped in "incremental improvement" rather than "paradigm reshaping."

Why Did the Lawsuit Reverse?

Gensing alleged "trade secret misappropriation"—claiming that when Fan founded Legendary Biopharm in 2017, he forwarded project reports to his personal email.

The Supreme Court's logic (inferred) likely was:

1. Knowledge Source: Those "project reports" were essentially Fan's intellectual output, not Gensing's proprietary asset. Technical proposals he wrote during his Legendary tenure legally constitute evolution of his "own knowledge" rather than "stolen secrets."

2. Transaction Hypothesis: Fan's compensation at Legendary was salary and equity, not "perpetual non-compete" agreements. Upon departure, absent explicit non-compete clauses, he retained the right to leverage his professional expertise for entrepreneurship.

3. Causation Proof: Gensing would need to prove Bay Island's success directly stemmed from that transferred document—nearly impossible to establish in technical innovation, where innovators inevitably build upon prior experience and cannot neatly partition "what came from old documents versus new creativity."

The Supreme Court's ruling essentially confirmed: innovators have the right to carry their technical knowledge to new ventures, provided no explicit perpetual non-compete was signed.

Why This Case Has Permanent Significance

This isn't China-specific—it's a structural paradox in global innovation ecosystems:

• Thiel & Musk: Musk left Compaq-acquired Zip2, founded X.com (later PayPal), then Tesla and SpaceX. Each move: "abandon old success, create new game."

• Steve Jobs & Pixar: Forced to leave Apple, he created animation's new paradigm. Had he remained, he'd optimize existing product lines.

• Ian Goodfellow & GANs: After incubating GANs inside Google without sufficient resource allocation, his move to OpenAI sparked generative AI's explosion.

The essence of the second curve: not founder disloyalty, but that success itself creates organizational rigidity. Genuine innovation requires breaking the boundaries that success defined.

What's Next for Bay Island Cells?

With $140 million funding, the goal isn't replicating Ciltacabtagene, but rather:

1. Cost Structure Innovation: CAR-T therapies currently price at $375,000-$475,000. Bay Island's funding scale signals pursuit of "half the cost, comparable efficacy" breakthroughs. This threatens the entire CAR-T market's pricing power.

2. Indication Expansion: Ciltacabtagene currently covers only hematologic malignancies. Next-generation must tackle solid tumors (lung, liver cancer)—3-5x technical difficulty, 10x market size.

3. Manufacturing Standardization: First-gen CAR-T is handcrafted per unit. Next-gen must be standardized, modular, mass-manufacturable. This requires GMP engineering, supply chain redesign, cost accounting rebuilt from scratch.

None of these could happen within Legendary's organizational framework—because the successful product already defined all decision priorities.

Lessons for Future Innovators

Fan's trajectory teaches us:

• Don't be blinded by success's halo: If you've created a landmark product at a company, the most dangerous moment isn't failure—it's success. The organization then mobilizes all resources to protect your success, not invest in the next wave.

• Leaving isn't betrayal: it's respect for innovation itself. Staying may feel comfortable, but gradually transforms you from "creator" into "administrator."

• Legal frameworks matter: Fan won because Chinese jurisprudence explicitly affirmed "innovators' migration rights" in this case. Other jurisdictions and eras might conclude differently. Understand your jurisdiction's definition of "IP boundaries" before timing your departure.